Cargando…
Case report of progressive renal dysfunction as a consequence of amiodarone-induced phospholipidosis
BACKGROUND: Amiodarone is associated with a range of unwanted effects on pulmonary, thyroid, and liver function. However, the nephrotoxic side effect caused by renal phospholipidosis has hardly received any attention up to now. CASE SUMMARY: This is a case of an 86-year-old Caucasian male with an ac...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516635/ https://www.ncbi.nlm.nih.gov/pubmed/37743903 http://dx.doi.org/10.1093/ehjcr/ytad457 |
_version_ | 1785109167996928000 |
---|---|
author | Duineveld, Mirjam D Kers, Jesper Vleming, Louis-Jean |
author_facet | Duineveld, Mirjam D Kers, Jesper Vleming, Louis-Jean |
author_sort | Duineveld, Mirjam D |
collection | PubMed |
description | BACKGROUND: Amiodarone is associated with a range of unwanted effects on pulmonary, thyroid, and liver function. However, the nephrotoxic side effect caused by renal phospholipidosis has hardly received any attention up to now. CASE SUMMARY: This is a case of an 86-year-old Caucasian male with an acute on chronic kidney disease 4 months after the initiation of amiodarone. A renal biopsy demonstrated the intracellular accumulation of phospholipids that have previously been demonstrated in association with organ dysfunction because of amiodarone use. Serum creatinine levels subsequently improved from 388 to 314 µmol/L after stopping amiodarone over the course of 2 months. DISCUSSION: In this case, a diagnosis of partially reversible acute on chronic kidney disease caused by lysosomal phospholipidosis due to amiodarone use was deemed highly likely. Lysosomal dysfunction leads to the accumulation of intra-lysosomal phospholipids (phospholipidosis). This accumulation is accompanied by progressive organ damage and dysfunction, including renal dysfunction, in rare instances. Guidelines advise regular surveillance for liver, lung, and thyroid toxicity during amiodarone treatment but do not mention the potential for renal toxicity. This case suggests that it might be prudent to include screening for renal toxicity in this surveillance. |
format | Online Article Text |
id | pubmed-10516635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105166352023-09-23 Case report of progressive renal dysfunction as a consequence of amiodarone-induced phospholipidosis Duineveld, Mirjam D Kers, Jesper Vleming, Louis-Jean Eur Heart J Case Rep Case Report BACKGROUND: Amiodarone is associated with a range of unwanted effects on pulmonary, thyroid, and liver function. However, the nephrotoxic side effect caused by renal phospholipidosis has hardly received any attention up to now. CASE SUMMARY: This is a case of an 86-year-old Caucasian male with an acute on chronic kidney disease 4 months after the initiation of amiodarone. A renal biopsy demonstrated the intracellular accumulation of phospholipids that have previously been demonstrated in association with organ dysfunction because of amiodarone use. Serum creatinine levels subsequently improved from 388 to 314 µmol/L after stopping amiodarone over the course of 2 months. DISCUSSION: In this case, a diagnosis of partially reversible acute on chronic kidney disease caused by lysosomal phospholipidosis due to amiodarone use was deemed highly likely. Lysosomal dysfunction leads to the accumulation of intra-lysosomal phospholipids (phospholipidosis). This accumulation is accompanied by progressive organ damage and dysfunction, including renal dysfunction, in rare instances. Guidelines advise regular surveillance for liver, lung, and thyroid toxicity during amiodarone treatment but do not mention the potential for renal toxicity. This case suggests that it might be prudent to include screening for renal toxicity in this surveillance. Oxford University Press 2023-09-14 /pmc/articles/PMC10516635/ /pubmed/37743903 http://dx.doi.org/10.1093/ehjcr/ytad457 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Case Report Duineveld, Mirjam D Kers, Jesper Vleming, Louis-Jean Case report of progressive renal dysfunction as a consequence of amiodarone-induced phospholipidosis |
title | Case report of progressive renal dysfunction as a consequence of amiodarone-induced phospholipidosis |
title_full | Case report of progressive renal dysfunction as a consequence of amiodarone-induced phospholipidosis |
title_fullStr | Case report of progressive renal dysfunction as a consequence of amiodarone-induced phospholipidosis |
title_full_unstemmed | Case report of progressive renal dysfunction as a consequence of amiodarone-induced phospholipidosis |
title_short | Case report of progressive renal dysfunction as a consequence of amiodarone-induced phospholipidosis |
title_sort | case report of progressive renal dysfunction as a consequence of amiodarone-induced phospholipidosis |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516635/ https://www.ncbi.nlm.nih.gov/pubmed/37743903 http://dx.doi.org/10.1093/ehjcr/ytad457 |
work_keys_str_mv | AT duineveldmirjamd casereportofprogressiverenaldysfunctionasaconsequenceofamiodaroneinducedphospholipidosis AT kersjesper casereportofprogressiverenaldysfunctionasaconsequenceofamiodaroneinducedphospholipidosis AT vleminglouisjean casereportofprogressiverenaldysfunctionasaconsequenceofamiodaroneinducedphospholipidosis |